'김갑성' 기자의 전체기사
-
Hon'ble CM of Delhi, Smt. Rekha Gupta, Inaugurates Apollo Athe…
NEW DELHI, Sept. 22, 2025 -- Apollo Hospitals Enterprise Ltd (AHEL) recently announced the launch of Apollo Athenaa – Asia's First Dedicated Cancer Centre for Women, located in E2-E3, Defence Colony, New Delhi. The centre was inaugurated by the Hon'ble Chief Minister of Delhi, Smt. Rekha Gupta, in the presence of Dr. Prathap C Reddy, Founder-Chairman, Apollo Hospitals Group; Ms. Bansuri Swaraj, Member of Parliament, New Delhi; Shri Neeraj Basoya, Member of the Legislative Assembly; Ms. Preetha Reddy, Executive Vice Chairperson, AHEL; and Mr. Harshad Reddy, Director, Group Oncology, AH
- 김갑성 기자
- 2025-09-22 15:43
-
PHASE Scientific Launches World's Largest Urine-Based Cerv…
GUANG'AN, China, Sept. 22, 2025 -- PHASE Scientific International Limited ("PHASE Scientific") today announced the official launch of the world's largest clinical study for urine-based cervical cancer (HPV) screening, with the first site established in Guang'an, Sichuan Province, China. This study is led by Peking University Shenzhen Hospital, with participation from West China Guang'an Hospital of Sichuan University and technical and diagnostic support by PHASE Scientific. The study applies PHASE Scientific's proprietary PHASiFY™ urine-based DNA concent
- 김갑성 기자
- 2025-09-22 15:39
-
Akeso Announces First Patient Dosed in Registrational Phas…
HONG KONG, Sept. 22, 2025 -- Akeso Inc. (9926.HK) has announced that the first patient has been dosed in its registrational Phase II study (AK130-202), evaluating AK130, a fully independently developed TIGIT/TGF-β bifunctional antibody fusion protein, in combination with ivonescimab (PD-1/VEGF bispecific antibody), for treating locally advanced or metastatic pancreatic cancer in patients who have failed up to two prior lines of systemic therapy. AK130 is the world's first and only TIGIT/TGF-β bifunctional antibody fusion protein in registrational clinical development. The initiation of
- 김갑성 기자
- 2025-09-22 14:51
-
First-in-Class Potential! FDA Clears IND Application for LBL-047, a…
NANJING, China, Sept. 22, 2025 -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company", Stock Code: 9887.HK) announced that the U.S. Food and Drug Administration (FDA) has approved its first-in-human Investigational New Drug (IND) application for LBL-047 on September 19, 2025. LBL-047 is a bispecific fusion protein composed of a humanized anti-blood dendritic cell antigen 2 (BDCA2) antibody and an engineered transmembrane activator and CAML interactor (TACI) ectodomain independently developed by Leads Biolabs. There are currently no approved clinical trials of
- 김갑성 기자
- 2025-09-22 12:29
-
Ascletis Announces ASC47 in Combination with Semaglutide D…
- The gastrointestinal (GI) tolerability of ASC47 in combination with semaglutide was significantly better than placebo in combination with semaglutide (semaglutide monotherapy). The incidence of vomiting was 6.7% in ASC47 in combination with semaglutide group compared to 57.1% in the semaglutide monotherapy group. - Ultra-long-acting subcutaneous (SQ) depot formulation of ASC47 demonstrated a lower rebound effect after treatment discontinuation compared to the semaglutide monotherapy group, supporting the potential use of once-monthly ASC47 as a maintenance therapy.&n
- 김갑성 기자
- 2025-09-22 08:10
-
Mabwell Bioscience and Aditum Bio Announce Formation of…
SHANGHAI and OAKLAND, Calif., Sept. 17, 2025 -- Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SH) and Aditum Bio today announced the launch of Kalexo Bio, a new company formed in conjunction with an exclusive global license agreement to develop 2MW7141, a novel dual-target siRNA candidate for lipid management in patients with dyslipidemia and for the prevention of high-risk atherosclerotic cardiovascular disease (ASCVD) events. Aditum Bio will provide funding for Kalexo Bio, and the parties will collaborate to advance 2MW7141 into clinical development. Kalexo Bio was founded by Aditu
- 김갑성 기자
- 2025-09-17 20:00
-
Alteogen Receives European Commission Approval for Aflibe…
EYLUXVI® is the second biosimilar approved for Alteogen following the launch of the Herceptin® biosimilar in China through its partner Qilu Pharmaceutical. DAEJEON, South Korea, Sept. 17, 2025 -- Alteogen Inc. (KOSDAQ:196170) announced today that the European Commission (EC) has granted marketing authorization for EYLUXVI® (code name: ALT-L9), an Eylea® biosimilar co-developed by its subsidiary, Alteogen Biologics. EYLUXVI® is Alteogen's second approved biosimilar, following the approval of the Herceptin® biosimilar, further expanding Alteogen's biosimi
- 김갑성 기자
- 2025-09-17 15:40
-
"EchoCare" Ultrasound Large Model Launched in Hong Ko…
HONG KONG, Sept. 17, 2025 -- Amid the global surge in rapid advancements in artificial intelligence, the healthcare sector is entering a critical phase of intelligent transformation. As a vital tool in clinical diagnosis, ultrasound imaging has long been plagued by issues such as low efficiency, inconsistent diagnostic standards, and insufficient AI model accuracy. These challenges urgently call for technological breakthroughs and industrial collaboration. Against this backdrop, Centre for Artificial Intelligence and Robotics (CAIR), Hong Kong Institute of Science & Innovation (HKISI), Ch
- 김갑성 기자
- 2025-09-17 13:32
-
Three WuXi Biologics Manufacturing Facilities Receive GMP C…
WUXI, China, Sept. 17, 2025 -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that three of its manufacturing facilities in Wuxi – MFG1, MFG2, and DP5 – have received GMP certification from Türkiye İlaç ve Tıbbi Cihaz Kurumu (TITCK). This marks the first GMP inspection conducted by Turkey's TITCK at WuXi Biologics. Achieving the certification underscores the company's commitment to upholding stringent international quality standards across its global network. During the five-day onsite inspection
- 김갑성 기자
- 2025-09-17 12:00
-
Kexing Biopharm's Human Umbilical Cord Mesenchymal Stem…
SHENZHEN, China, Sept. 17, 2025 -- Kexing Biopharm announced that its investigational Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes has successfully completed a Type II Drug Master File (DMF) registration with the U.S. FDA. Exosomes, as a next-generation bioactive carrier, boast unique advantages such as low immunogenicity, strong tissue penetration, and potential for targeted modification, offering immense promise for medical applications. However, the technical barriers and research challenges in Exosome development place them at the forefront of complexity among bioact
- 김갑성 기자
- 2025-09-17 10:30
- 1포리프 굿마팻 (누바디 굿바이 마이팻) 다이어트 건강기능식품 출시
- 22021년 식품분석전문가 1급/2급 검정자격시험 안내
- 3투썸플레이스, 초콜릿 애프리콧 무스 출시
- 4만성질환자들의 유료독감백신접종에 정책적인 배려가 필요하다
- 5아임웹, CRM 기능 출시… 고객 행동 데이터 기반 마케팅 지원
- 6하만카돈, AURA STUDIO 4 블루투스 스피커 출시
- 7대구오페라하우스 - 20주년 기념 골든 보이스 시리즈Ⅲ, 테너 콘서트
- 82021년 대학생기자단 모집
- 9대한약물영양의학회 2020년 추계학술대회
- 10대한영양제처방학회 춘계학술대회 성황리에 마쳐
2025-10-19_SUN
- Multitude Therapeutics Announces Encouraging Interim Phase I/II Results from Ongoing First-in-Human Study Evaluating its MUC18-directed Antibody-Drug-Conjugate, AMT-253, in Melanoma and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting 15:00
- Case Report | Preliminary Clinical Data of CARsgen's Allogeneic BCMA CAR-T Product CT0596 for the Treatment of Primary Plasma Cell Leukemia 14:00
- From Wellbeing to Academics: Why HK Parents Are Hitting Pause on Kids' Social Media and Device Use 13:00
- 내면의 조화를 발견하세요: '원더풀 인도네시아 웰니스 페스티벌 2025' 개최 01:50
- 제2회 마나르 아부다비 출품 작가 명단 공개 00:48
- 중국-피지 어업 협력, 섬나라 경제 활력 끌어올리다 00:00
2025-10-18_SAT
발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.
UPDATE: 2025년 10월 19일 16시 40분